Susquehanna Fundamental Investments LLC Lowers Holdings in Natera, Inc. (NASDAQ:NTRA)

Susquehanna Fundamental Investments LLC lowered its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 18.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,327 shares of the medical research company’s stock after selling 7,106 shares during the quarter. Susquehanna Fundamental Investments LLC’s holdings in Natera were worth $3,501,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Itau Unibanco Holding S.A. bought a new position in Natera in the 2nd quarter worth approximately $28,000. GAMMA Investing LLC boosted its position in shares of Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after acquiring an additional 108 shares during the last quarter. YHB Investment Advisors Inc. purchased a new position in Natera during the first quarter valued at $36,000. Tobam bought a new stake in Natera in the 2nd quarter valued at $74,000. Finally, DekaBank Deutsche Girozentrale bought a new stake in Natera in the 1st quarter valued at $83,000. Institutional investors own 99.90% of the company’s stock.

Natera Stock Performance

NTRA stock opened at $125.72 on Monday. Natera, Inc. has a twelve month low of $36.90 and a twelve month high of $132.01. The firm has a market cap of $15.44 billion, a price-to-earnings ratio of -40.29 and a beta of 1.53. The business’s fifty day simple moving average is $115.98 and its two-hundred day simple moving average is $106.75. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The company had revenue of $413.35 million during the quarter, compared to analysts’ expectations of $343.00 million. During the same period in the previous year, the company earned ($0.97) EPS. The firm’s quarterly revenue was up 58.1% on a year-over-year basis. Analysts predict that Natera, Inc. will post -1.96 earnings per share for the current year.

Insider Buying and Selling at Natera

In other news, CEO Steven Leonard Chapman sold 5,496 shares of the stock in a transaction on Monday, July 15th. The stock was sold at an average price of $111.66, for a total transaction of $613,683.36. Following the transaction, the chief executive officer now owns 207,855 shares of the company’s stock, valued at approximately $23,209,089.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Natera news, insider Solomon Moshkevich sold 549 shares of the stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $105.16, for a total transaction of $57,732.84. Following the sale, the insider now owns 113,637 shares of the company’s stock, valued at approximately $11,950,066.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 5,496 shares of the business’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $111.66, for a total value of $613,683.36. Following the completion of the transaction, the chief executive officer now directly owns 207,855 shares of the company’s stock, valued at $23,209,089.30. The disclosure for this sale can be found here. Insiders sold a total of 48,738 shares of company stock valued at $5,663,574 in the last ninety days. Corporate insiders own 7.60% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on NTRA shares. Jefferies Financial Group initiated coverage on Natera in a research report on Monday, June 3rd. They set a “buy” rating and a $142.00 price objective for the company. Piper Sandler reaffirmed an “overweight” rating and issued a $150.00 price objective on shares of Natera in a research note on Friday, September 13th. Morgan Stanley upped their price objective on Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a report on Wednesday, August 28th. Finally, Stephens reaffirmed an “overweight” rating and set a $125.00 price target on shares of Natera in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $120.07.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.